Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia
An overview of the latest Saudi evidence presented at ESPID 2026.
Learn more
HomeArticles
Latest Articles
Real-World Effectiveness of Nirsevimab
The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.
Learn more
Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons
Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across two consecutive RSV seasons
Learn more
Expanding RSV Protection in Kuwait
Summary of Kuwait’s updated RSV prevention policy
Learn more
IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.1-3
Learn more
GOLD 2026 Report: Key Updates for COPD Management
What’s New in the GOLD 2026 Report
Learn more
Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer
Kaplan–Meier curves play a key role in visualizing how clinical events—such as confirmed disability progression—evolve over time in MS studies. In this video, Dr. Barry Singer provides a clear, simplified walkthrough of how these curves are constructed, how patient data contributes to each step, and what curve separation really tells us about treatment impact. This resource offers an accessible foundation for anyone looking to better understand KM interpretation in MS research.
Learn more
Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer
A simplified walkthrough of how 6‑month Confirmed Disability Progression (CDP) is measured in MS clinical trials. Dr. Barry Singer explains how EDSS changes are assessed, why sustained progression matters, and how this endpoint helps distinguish real, lasting disability worsening from temporary fluctuations.
Learn more